trial

Magnetic Seizure Therapy for Schizophrenia - Trial

NCTId NCT06672588
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Recruiting
Enrollment 80 (estimated)
Sponsored by Centre for Addiction and Mental Health
Primary completion 2028-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Recruiting
Enrollment
80 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2025-04-22
Primary completion
2028-11
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
Magnetic Seizure Therapy (MST)Electroconvulsive Therapy (ECT)

Sponsors

Centre for Addiction and Mental HealthLead Sponsor
University of British ColumbiaCollaborator

Investigators

1
Daniel H. Mathalon, Ph.D., M.D.Principal Investigator

Sites

2 total
Vancouver, CanadaToronto, Canada

Facts & assertions

4 sourced
Enrollment
80
Phase
NA
Primary Completion Date
2028-11
Status
RECRUITING
relationships
The graph out of here
drug
Magnetic Seizure Therapy (MST)
drug
Electroconvulsive Therapy (ECT)
drug
lead_sponsor
Centre for Addiction and Mental Health
company
collaborator
University of British Columbia
company
indication
Treatment Resistant Schizophrenia
indication
Schizoaffective Disorder
indication
Psychotic Disorders
indication
investigator
Daniel H. Mathalon, Ph.D., M.D.
person